N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury...

Area of Science:

• Critical Care Medicine
• Nephrology
• Pharmacology

Background:

• Shock is a critical condition often leading to acute kidney injury (AKI).
• N-acetylcysteine (NAC) and deferoxamine (DFX) are investigated for their potential protective effects against organ damage.
• The study focuses on critically ill patients experiencing new-onset hypotension.

Purpose of the Study:

• To evaluate the efficacy of combined N-acetylcysteine (NAC) and deferoxamine (DFX) in preventing acute kidney injury (AKI) in patients with shock.
• To test the primary hypothesis that NAC plus DFX treatment decreases AKI incidence.

Main Methods:

• A double-blind, randomized, placebo-controlled trial involving 80 critically ill patients.
• Patients received either NAC plus DFX or a placebo intravenously.
• The primary outcome measured was the incidence of acute kidney injury (AKI).

Main Results:

• The incidence of AKI was 67% in the placebo group and 65% in the NAC plus DFX group (RR 0.89).
• The combination treatment did not significantly decrease the overall incidence of AKI.
• However, NAC plus DFX reduced the severity and duration of AKI and lowered serum creatinine levels at discharge.

Conclusions:

• Combined administration of NAC and DFX did not reduce the incidence of AKI in critically ill patients with new-onset hypotension.
• The treatment may offer benefits in mitigating AKI severity and duration, possibly by reducing inflammation and oxidative stress.